close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

170.64 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Unusual volume S&P500 stocks in Wednesday's session
Let's have a look at the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization
Charles River shares rise after Q1 adjusted EPS and revenue top estimates; company raises 2025 outlook and adds four directors to its board. 
Via Benzinga
Topics Earnings
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Which S&P500 stocks are moving before the opening bell on Wednesday?
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses. 
Via Chartmill
These stocks that are showing activity before the opening bell on Wednesday.
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Charles River Laboratories’s (NYSE:CRL) Q1: Strong Sales, Stock Jumps 22.4%
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 2.7% year on year to $984.2 million. Its non-GAAP... 
Via StockStory
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Charles River Laboratories Announces First-Quarter 2025 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories (CRL) To Report Earnings Tomorrow: Here Is What To Expect
Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results tomorrow before the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?
 
Via Benzinga
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
From Charles River Laboratories International, Inc.
Via Business Wire
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
9 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
From Charles River Laboratories International, Inc.
Via Business Wire
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead? 
Via MarketBeat
Topics ETFs Economy Government
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Explore the top gainers and losers within the S&P500 index in today's session.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday. 
Via Chartmill
Wall Street Pulls Back After Early Gains As Tariff Uncertainties Persist: What's Driving Markets Monday?
Wall Street pared early morning gains by midday Monday, as investor caution returned despite a temporary easing in U.S.-China trade tensions. While the initial market reaction was positive, especially... 
Via Benzinga
Topics World Trade
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
Which S&P500 stocks are moving on Friday?
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday?
Wall Street bounced back from early losses, driven by upbeat bank earnings and cooler inflation data, while shrugging off trade war concerns. 
Via Benzinga
Topics Economy World Trade
FDA’s Intent To Phase Out Animal Testing Requirement Weighs Down Charles River Stock: Retail’s Disheartened
JPMorgan, which holds a ‘Neutral’ rating on the stock, opined that Charles River could see disruption from customers reassessing its preclinical strategies in the near term. 
Via Stocktwits
Topics Animal Testing
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency. 
Via Benzinga
Topics Animal Testing Artificial Intelligence
These S&P500 stocks that are showing activity before the opening bell on Friday.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today